<DOC>
	<DOCNO>NCT03017690</DOCNO>
	<brief_summary>An observational time motion study clinical oncology set utilized order measure compare product attribute overall product efficiency lanreotide octreotide LAR .</brief_summary>
	<brief_title>Lanreotide Octreotide Long Acting Release ( LAR ) Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors ( GEP-NETs )</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>Men woman must 18 year age older A current diagnosis advance , unresectable GEPNET Provided write informed consent participate study Currently receive lanreotide octreotide LAR receive least one prior injection current somatostatin analogue ( SSA ) . Receiving treatment lanreotide octreotide LAR part clinical trial Scheduled receive dose lanreotide octreotide LAR would necessitate 1 injection day Scheduled receive treatment infusion center/room day part appointment Known hypersensitivity somatostatin analogue</criteria>
	<gender>All</gender>
	<minimum_age>18 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>